Absci Corporation

NASDAQ:ABSI

Biotechnology

Healthcare
$8.18 +1.04%

+$0.08 today

Market cap
$1.41B
Beta
2.46
P/E (TTM)
-9.4
EPS (TTM)
-$0.77
52W Low $2.24High $8.17

Volume 5.66M

Average 5.10M

ABSI Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Absci CorporationNASDAQ: ABSI

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue declines year over year

Q1 FY2026 cost of revenue of $2.73M fell 83.3% year over year, behind the -49.9% change in trailing-twelve-month cost of revenue. Sequentially, it fell 3.5% from the prior quarter. Over 3 fiscal years it compounded at -41.6% a year.

Context

  • Cost of revenue amounted to 419.4% of revenue in FY2025, down 958.2 pp from a year earlier.
  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -83.3% toward the trailing-twelve-month pace of -49.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.73M-3.5% QoQ
Last fiscal yearDec 2025
$11.74M-81.2% YoY
LTMMar 2026
$26.01M-49.9% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-83.3%——
1 year-81.2%——
3-year CAGR-41.6%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
11.74M USD
Year-over-year change
-81.2%
4-year CAGR
-28.4%

Cost of Revenue vs competitors

How ABSI compares with its peers on the latest reported figures

  • ABSI's LTM Mar 2026 cost of revenue of $26.01M is the 2nd highest of the 3 companies compared; the peer median is $40.26M.
  • Cost of revenue amounts to 1416.9% of revenue for ABSI, versus a peer median of 59.3%.
ABSI Competitors Peer median
Cost of Revenue for ABSI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABCLAbCellera Biologics Inc.LTM Sep 2026$80.53M —-24.3%118.7%
ABSIAbsci CorporationLTM Mar 2026$26.01M -49.9%-41.6%1416.9%
GENBGenerate Biomedicines, Inc.FY2025$0 ——0.0%
Peer median (excluding ABSI) $40.26M—-24.3%59.3%

Competitors are the stored peer set for ABSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.78M5.75M5.72M4.53M2.8M
Cost of Revenue44.59M58.91M47.57M62.46M11.74M
Gross Profit(39.8M)(53.16M)(41.85M)(57.93M)(8.94M)
Gross Margin-832.4%-925.0%-731.9%-1277.6%-319.4%
Research & Development44.59M58.91M48.07M63.86M81.42M
Selling, General & Admin000035.06M
Operating Expenses35.43M53.59M73.67M50.96M115.78M
Depreciation & Amortization6.65M13.04M14M13.39M11.74M
EBITDA(67.68M)(91.36M)(79.68M)(94.1M)(103.16M)
EBITDA Margin-1415.4%-1589.6%-1393.5%-2075.4%-3684.4%
Operating Income(75.24M)(106.75M)(115.52M)(108.89M)(124.72M)
Operating Margin-1573.4%-1857.5%-2020.2%-2401.6%-4454.2%
Interest Income00000
Interest Expense3.43M972K1.01M565K209K
Other Income / Expenses(34.62M)1.39M5.05M5.85M9.6M
Income Before Tax(109.86M)(105.37M)(110.47M)(103.04M)(115.11M)
Pre-Tax Margin-2297.3%-1833.4%-1931.9%-2272.5%-4111.2%
Income Tax Expense(8.9M)(461K)100K70K69K
Net Income(100.96M)(104.9M)(110.57M)(103.11M)(115.18M)
Net Margin-2111.3%-1825.4%-1933.6%-2274.1%-4113.7%
EPS (Basic)(1.11)(1.15)(1.20)(0.94)(0.84)
EPS (Diluted)(1.11)(1.15)(1.20)(0.94)(0.84)
Weighted Avg Shares92.65M90.85M92.03M110.24M136.78M
Weighted Avg Shares (Diluted)92.65M90.85M92.03M110.24M136.78M

Absci Corporation

NASDAQ:ABSI

Intrinsic Alpha fair value

Locked

Current Price

$8.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.